Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This personalized data helps you and your provider choose the right supplement dosages and timing
Focusing on lean protein, whole grains, healthy fats, and plenty of vegetables can help support steady progress
Robert Steinbrook, director of the Public Citizen Health Research Group, terms GLP-1 agonists for weight loss a real-time experiment with unknown long-term risks
All information regarding this product provided on our website is purely educational
We accept insurance and handle prior authorization on your behalf
Molecular Identity Developer Eli Lilly Brand Names Mounjaro (diabetes), Zepbound (obesity) Mechanism Dual GLP-1 and GIP receptor agonist FDA Status Approved (2022 diabetes, 2023 obesity) Administration Weekly subcutaneous GIP Receptor Pathway The GIP receptor activation in Tirzepatide provides different metabolic effects than glucagon: Incretin enhancement: GIP augments GLP-1's insulin-related signaling Adipose tissue effects: GIP receptor expression in fat tissue documented Tolerability profile: Some research suggests GIP may moderate GI effects Synergistic incretin signaling: Two incretin pathways vs
US$ 21.90
US$ 23.08
US$ 24.11
US$ 21.10
US$ 26.49
US$ 25.84
US$ 29.74
US$ 21.60
US$ 22.31
